Prostatic Neoplasms
Conditions
Keywords
Prostatic neoplasms, Locally advanced, Radiotherapy, Surgery, Mortality
Brief summary
This prospective, open randomized phase III surgical trial seeks to study whether radical prostatectomy (with or without the combination of external radiation) improves prostate-cancer specific survival in comparison with primary radiation treatment and hormonal treatment among patients diagnosed with locally advanced (T3) prostate cancer. Untreated or conservatively treated locally advanced prostate cancer is associated with high mortality. Modern curative treatment for advanced solid malign tumors include surgery and/or radiation plus attempted chemotherapy if available to achieve both local control and elimination of potential micro metastases. Whereas there is evidence that surgery can cure localized prostate cancer, there are no clinical trials of multi-modal treatment of locally advanced prostate cancer that includes surgical removal of the prostate. One potential advantage of adding prostatectomy to the treatment of LAPC is that removing the prostate enables a full pathological assessment of the tumor characteristics and thus a better estimation of the risk of recurrence. Surgical treatment could thus reduce the numbers needed to treat with chemotherapy and radiation, and thus improve quality of life after treatment. In addition, evidence indicate that residual cancer in the prostate occurs in 25% after radiation treatment (56) and surgical removal of the prostate may improve survival beyond what can be achieved by radiation and ADT. On the other hand, patients treated with surgery, radiation and hormones will experience side effects of all three treatment modalities and might fare better if radiotherapy plus hormones can provide oncological control without prior surgery. A randomized clinical trial comparing two multimodal treatment regimens of which one includes a radical prostatectomy is therefore warranted.
Interventions
PROCEDUREProstatectomy/Surgery
Radical prostatectomy with or without adjuvant or salvage radiotherapy
OTHERRadiotherapy with adjuvant androgen deprivation therapy
Radiotherapy with adjuvant androgen deprivation therapy
Sponsors
Olof Akre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age ≤75, at the time of randomization * Diagnosed histopathologically confirmed and untreated prostatic adenocarcinoma * The general condition and mental status of patients shall permit observation in accordance with the study protocol * Tumor stage (T, M, N): T3 stage (as indicated by digital rectal examination or MR imaging or other validated imaging technique) T4 tumors can be included if considered resectable/treatable on MR imaging Significant extra-capsular tumor extension in biopsy (rare but acceptable for inclusion) M0 (no sign of distant metastases) confirmed by bone scan or CT or MRT of axial skeleton (at a maximum of pelvis and lumbar vertebral column) N0 stage, defined in accordance to the RECIST guidelines as no sign of macroscopic retroperitoneal lymph-node metastases \>=1.5 cm (short axis) on CT scan, PET-CT, or MRT or more than one suspected lymph-node metastases Presence Gleason grade pattern 4 or 5 \- Signed Informed consent
Exclusion criteria
* Patients with a PSA value of \> 100 ng/mL * Any medical condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives Patients with contraindications for either prostatectomy or radiotherapy to the prostate are not eligible for the study. Most contraindications for these treatments are relative, but in general, radiotherapy may be precluded among patients with: * Anorectal disease, such as fistulae, Crohn´s disease, and ulcerative colitis * Significant obstructive lower urinary tract symptoms * Proximal stricture of the urethrae * Severe neurogenic bladder dysfunction * Enlarged prostate beyond 70-90 ml * Previous radiotherapy to the pelvic region On the other hand, surgery may be precluded among patients with: * Massive local tumor progression, particularly in the apical region * Massive abdominal obesity * Contraindications to anesthesia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cause specific survival | Up to 10 years | Cause-specific survival (CSS) will be calculated as 1-cause specific mortality. Mortality and mortality causes will be ascertained from the nationwide Cause-of-Death Register. In the absence of a functioning Cause-of-Death register, an endpoint committee of at least 2 medical doctors will determine the cause of death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Metastasis free survival | Up to 10 years | Composite endpoint of time to metastasis and survival |
| Quality of life - general psychological, urinary, bowel and sexual health | At 1,2,5 and 10 years after randomization | Questionnaire-based evaluation of general psychological health, urinary health, bowel health, and sexual health. Questions about self Questions about quality of life in the past month (scale 1 to 7; 1=no quality, 7=the best quality) Depression and anxiety (scale 1 to 7; 1=no, 7=very) Symptom Form (EPIC-26) (scale 1 to 5; 1= no problem, 5=major problem) Questions about the urinary tract Questions about sexual function Questions about bowel function Questions about prostate cancer - diagnosis and treatment Questions about prostate cancer check-ups Questions about hormone/castration therapy and its significance Questions about pain and lymph swelling |
| Overall survival | Up to 10 years | Overall survival (OS) will be calculated as 1-overall mortality. Mortality data will be ascertained through the nationwide Cause-of-Death Register. |
| Time to biochemical progression | Up to 10 years | Ascertained at follow-up visits |
| Adverse events | Up to 10 years | Ascertained at visits |
| Cardiovascular disease | Up to 10 years | Data from national PcBaSe-register (https://snd.gu.se/en/catalogue/study/ext0014), a registry where the national prostate cancer registry (NPCR, www.npcr.se) has been linked to the Swedish National Cancer Register, the Cause of Death Register, the Prescribed Drug Register, the National Patient Register, and the Acute Myocardial Infarction Register, the Register of the Total Population, the Longitudinal Integration database for health insurance and labour market studies (LISA), the Multi-Generatioon Register and several other population-based registers. |
| Time to castration-resistant prostate cancer | Up to 10 years | Ascertained at follow-up visits |
Other
| Measure | Time frame | Description |
|---|---|---|
| Health-care consumption | Annually up to 10 years | Annual Defined Daily Dose (DDD) of analgesics, prescription databases |
Countries
Denmark, Finland, Norway, Sweden
Contacts
Primary ContactOlof Akre, Prof.
Outcome results
None listed